MIRA INFORM REPORT
|
Report Date : |
01.07.2013 |
IDENTIFICATION DETAILS
|
Name : |
TEIJIN PHARMA LTD |
|
|
|
|
Registered Office : |
Kasumigaseki Common Gate West, 3-2-1 Kasumigaseki Chiyodaku 100-0013 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.03.2012 |
|
|
|
|
Date of Incorporation : |
0100-01-078242 |
|
|
|
|
Com. Reg. No.: |
April, 2002 |
|
|
|
|
Legal Form : |
Limited Company |
|
|
|
|
Line of Business : |
Mfg of pharmaceuticals, pharmaceutical devices |
|
|
|
|
No. of Employees : |
1,869 |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Status : |
Good |
|
Payment Behaviour : |
Regular |
|
Litigation : |
Clear |
NOTES:
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March, 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
japan - ECONOMIC OVERVIEW
In the years following World War II, government-industry
cooperation, a strong work ethic, mastery of high technology, and a
comparatively small defense allocation (1% of GDP) helped Japan develop a
technologically advanced economy. Two notable characteristics of the post-war
economy were the close interlocking structures of manufacturers, suppliers, and
distributors, known as keiretsu, and the guarantee of lifetime employment for a
substantial portion of the urban labor force. Both features are now eroding
under the dual pressures of global competition and domestic demographic change.
Japan's industrial sector is heavily dependent on imported raw materials and
fuels. A small agricultural sector is highly subsidized and protected, with
crop yields among the highest in the world. While self-sufficient in rice
production, Japan imports about 60% of its food on a caloric basis. For three
decades, overall real economic growth had been spectacular - a 10% average in
the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth
slowed markedly in the 1990s, averaging just 1.7%, largely because of the after
effects of inefficient investment and an asset price bubble in the late 1980s
that required a protracted period of time for firms to reduce excess debt,
capital, and labor. Modest economic growth continued after 2000, but the
economy has fallen into recession three times since 2008. A sharp downturn in
business investment and global demand for Japan's exports in late 2008 pushed
Japan into recession. Government stimulus spending helped the economy recover
in late 2009 and 2010, but the economy contracted again in 2011 as the massive
9.0 magnitude earthquake and the ensuing tsunami in March disrupted
manufacturing. The economy has largely recovered in the two years since the
disaster, but reconstruction in the Tohoku region has been uneven.
Newly-elected Prime Minister Shinzo ABE has declared the economy his
government's top priority; he has pledged to reconsider his predecessor's plan
to permanently close nuclear power plants and is pursuing an economic
revitalization agenda of fiscal stimulus and regulatory reform and has said he
will press the Bank of Japan to loosen monetary policy. Measured on a
purchasing power parity (PPP) basis that adjusts for price differences, Japan
in 2012 stood as the fourth-largest economy in the world after second-place
China, which surpassed Japan in 2001, and third-place India, which edged out
Japan in 2012. The new government will continue a longstanding debate on
restructuring the economy and reining in Japan's huge government debt, which
exceeds 200% of GDP. Persistent deflation, reliance on exports to drive growth,
and an aging and shrinking population are other major long-term challenges for
the economy.
|
Source
: CIA |
TEIJIN PHARMA LTD
Teijin Pharma KK
Kasumigaseki Common Gate West, 3-2-1 Kasumigaseki Chiyodaku 100-0013
JAPAN
Tel: 03-3506-4077 Fax:
03-3506-4498
URL: http://www.teijin-pharma.co.jp
E-Mail address: (thru the URL)
Mfg of pharmaceuticals, pharmaceutical devices
83 locations nationwide
USA (2), UK, Korea, China (2), Spain
Iwakuni (2)
HIROSHI UNO, PRES Hidekazu
Kuribayashi, s/mgn dir
Kenichi Masuda, dir Tomohiro
Ohta, dir
Noriaki Endoh, dir Akihisa
Nabeshima, dir
Yen Amount: In million Yen,
unless otherwise stated
FINANCES FAIR A/SALES Yen 104,744 M
PAYMENTS REGULAR CAPITAL Yen
10,000 M
TREND UP WORTH Yen 43,084 M
STARTED 2002 EMPLOYES 1,869
MFR OF PHARMACEUTICALS, WHOLLY OWNED BY TEIJIN LTD.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS
ENGAGEMENTS.
The subject company was established on the basis of a division separated
from Teijin Ltd (See REGISTRATION). This firm specializes in mfg pharmaceuticals
& medical devices for: bone & joint diseases, respiratory diseases,
cardiovascular & metabolic diseases, other.
In addition, the firm developed home medical care services, home oxygen
therapy continuous positive airway pressure (CPAP) therapy, a treatment for
sleep apnea syndrome, and now holds the largest share in each domestic market. Entered into market alliance with Astellas
Pharma China Inc, and Astellas Pharma Hong Kong Co Ltd.
The sales volume for Mar/2012 fiscal term amounted to Yen 104,744
million, a 3% up from Yen 99,699 million in the previous term. Demand for home medical care services was
brisk and rose. New pharmaceuticals
gradually contributed. The recurring
profit was posted at Yen 26,411 million and the net profit at Yen 14,772
million, respectively, compared with Yen 24,808 million recurring profit and
Yen 14,731 million net profit, respectively, a year ago.
For the term that ended Mar 2013 the recurring profit was projected at
Yen 27,000 million and the net profit at Yen 15,000 million respectively, on a
2% rise in turnover, to Yen 105,000 million.
Final results are yet to be released.
The financial situation is considered FAIR and good for ORDINARY
business engagements.
Date Registered: Apr
2002
Regd No.: 0100-01-078242
(Tokyo-Chiyodaku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 800,000 shares
Issued:
200,000 shares
Sum: Yen
10,000 million
Major shareholders
(%): Teijin Ltd* (100)
*.. Major synthetic textile mfr, Tokyo, founded 1918, listed Tokyo S/E,
capital Yen 70,816 million, sales Yen 745,712 million, operating profit Yen
12,357 million, recurring profit Yen 9,786 million, net losses Yen 29,130
million, total assets Yen 762,399 million, net worth Yen 292,127 million,
employees 16,797, pres Shigeo Ohyagi
Nothing detrimental is known as to the commercial morality of
executives.
Activities: Manufactures
pharmaceuticals & medical devices for: bone & joint diseases,
respiratory diseases, cardiovascular & metabolic diseases; home care
medical services, home oxygen therapy, other (--100%).
Clients: [Mfrs,
wholesalers] Teijin Home-Care Therapy, Kaketsuken Corp, Sakai Inc, Japan Care
Service Group, other
No. of accounts: 500
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs,
wholesalers] Teijin Ltd, Kaketsuken Corp, Fuji Bio Medix, Nichiko Pharma,
Morishita Jintan Co, Asuka Pharmaceutical Co, other
Payment record: Regular
Location: Business area in
Tokyo. Office premises at the caption
address are leased and maintained satisfactorily.
Bank References:
MUFG (Tokyo)
Relations: Satisfactory
(In Million Yen)
|
Terms Ending: |
31/03/2013 |
31/03/2012 |
31/03/2011 |
31/03/2010 |
|
|
Annual
Sales |
|
105,000
|
102,744
|
99,669
|
96,992
|
|
Recur.
Profit |
|
27,000
|
26,411
|
24,808
|
24,085
|
|
Net
Profit |
|
15,000
|
14,772
|
14,731
|
13,500
|
|
Total
Assets |
|
|
79,667
|
75,609
|
70,556
|
|
Current
Assets |
|
|
44,070
|
43,012
|
45,285
|
|
Current
Liabs |
|
|
30,197
|
26,335
|
25,489
|
|
Net
Worth |
|
|
43,084
|
43,181
|
44,547
|
|
Capital,
Paid-Up |
|
|
10,000
|
10,000
|
10,000
|
|
Div.P.Share(¥) |
|
|
0.00 |
0.00 |
0.00 |
|
<Analytical
Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
2.20 |
3.09 |
2.76 |
0.00 |
|
|
Current Ratio |
|
.. |
145.94
|
163.33
|
177.66
|
|
N.Worth Ratio |
.. |
54.08
|
57.11
|
63.14
|
|
|
R.Profit/Sales |
|
25.71
|
25.71
|
24.89
|
24.83
|
|
N.Profit/Sales |
14.29
|
14.38
|
14.78
|
13.92
|
|
|
Return On Equity |
.. |
34.29
|
34.11
|
30.31
|
|
Notes: Forecast (or estimated) figures for the 31/03/2013 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.59.70 |
|
|
1 |
Rs.91.14 |
|
Euro |
1 |
Rs.77.97 |
INFORMATION DETAILS
|
Report Prepared
by : |
SDA |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.